Brief Research Report
Accepted on 23 Oct 2024
Superior Survival Benefits of Triple Combination Immunotherapy Compared to Standard Chemotherapy as Second-Line Treatment for Advanced Biliary Tract Cancer: A Retrospective Analysis
in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers